224 related articles for article (PubMed ID: 35822370)
1. [Progress in diagnosis and treatment of neurofibromatosis in children].
Wang S; Li Y; Zhang J; Ni X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2022 Jun; 36(6):477-482. PubMed ID: 35822370
[No Abstract] [Full Text] [Related]
2. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
[TBL] [Abstract][Full Text] [Related]
3. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
4. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas.
Kluwe L; Friedrich RE; Mautner VF
Cancer Genet Cytogenet; 1999 Aug; 113(1):65-9. PubMed ID: 10459349
[TBL] [Abstract][Full Text] [Related]
6. [Unusual clinical manifestations of type 1 neurofibromatosis].
Komlósi K; Polgár N; Hadzsiev K; Ottóffy G; Illés T; Dóczi T; Melegh B
Orv Hetil; 2011 Dec; 152(49):1965-70. PubMed ID: 22106164
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
8. Severe plexiform facial neurofibromatosis, type 1 with underdeveloped eyes and a novel NF1 mutation.
Kantaputra PN; van den Ouweland A; Sangruchi T; Limwongse C
Am J Med Genet A; 2012 Jul; 158A(7):1750-3. PubMed ID: 22678692
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
[TBL] [Abstract][Full Text] [Related]
11. Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview.
Packer RJ; Rosser T
J Child Neurol; 2002 Aug; 17(8):638-41; discussion 646-51. PubMed ID: 12403563
[TBL] [Abstract][Full Text] [Related]
12. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
[TBL] [Abstract][Full Text] [Related]
13. [From gene to disease; neurofibromatosis type 1].
de Goede-Bolder A; Cnossen MH; Dooijes D; van den Ouweland AM; Niermeijer MF
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1736-8. PubMed ID: 11572174
[TBL] [Abstract][Full Text] [Related]
14. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
16. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
18. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.
Däschner K; Assum G; Eisenbarth I; Krone W; Hoffmeyer S; Wortmann S; Heymer B; Kehrer-Sawatzki H
Biochem Biophys Res Commun; 1997 May; 234(2):346-50. PubMed ID: 9177273
[TBL] [Abstract][Full Text] [Related]
19. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.
Kokkinou E; Roka K; Alexopoulos A; Tsina E; Nikas I; Krallis P; Thanopoulou I; Nasi L; Makrygianni E; Tsoutsou E; Kosma K; Tsipi M; Tzetis M; Frysira H; Kattamis A; Pons R
Postgrad Med; 2019 Sep; 131(7):445-452. PubMed ID: 31443616
[TBL] [Abstract][Full Text] [Related]
20. Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene.
Veres K; Bene J; Hadzsiev K; Garami M; Pálla S; Happle R; Medvecz M; Szalai ZZ
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]